Display options
Cite
Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010;4:147-58doi: 10.2147/dddt.s7667.
Giembycz, M. A., & Field, S. K. (2010). Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug design, development and therapy, 4147-58. https://doi.org/10.2147/dddt.s7667
Giembycz, Mark A, and Field, Stephen K. "Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD." Drug design, development and therapy vol. 4 (2010): 147-58. doi: https://doi.org/10.2147/dddt.s7667
Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667. PMID: 20689641; PMCID: PMC2915539.
Copy Download .nbib Format: NLM
Share it on

Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Drug design, development and therapy

Mark A Giembycz, Stephen K Field

Affiliations

  1. Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Alberta, Canada.

PMID: 20689641 PMCID: PMC2915539 DOI: 10.2147/dddt.s7667

Abstract

In April 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the "maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV(1) postbronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment". This decision was based, in part, on the results of several large, international, multicenter, randomized, placebo-controlled trials of either six or 12 months' duration that had been undertaken in COPD patients. Roflumilast 500 mug daily improved lung function and reduced exacerbations in patients with more severe COPD, especially those with chronic bronchitis, frequent exacerbations, or who required frequent rescue inhaler therapy in the placebo-controlled trials. It also improved lung function and reduced exacerbations in patients with moderately severe COPD treated with salmeterol or tiotropium. Advantages of roflumilast over inhaler therapy are that it is an oral tablet and only needs to be taken once daily. While taking roflumilast, the most common adverse effects patients experienced were gastrointestinal upset and headache. Weight loss, averaging 2.2 kg, occurred in patients treated with roflumilast. Patients taking roflumilast were more likely to drop out of the trials than patients in the control groups. Patients who discontinued therapy usually did so during the first few weeks and were more likely to have experienced gastrointestinal side effects. Roflumilast is the first selective phosphodiesterase 4 inhibitor and will offer physicians another treatment option for patients with more severe COPD.

Keywords: chronic obstructive pulmonary disease; exacerbation; phosphodiesterase 4 inhibitor; roflumilast

References

  1. Am J Respir Crit Care Med. 2002 May 15;165(10):1371-6 - PubMed
  2. N Engl J Med. 2007 Feb 22;356(8):775-89 - PubMed
  3. Am J Respir Crit Care Med. 1996 Mar;153(3):967-75 - PubMed
  4. Lancet. 2009 Aug 29;374(9691):685-94 - PubMed
  5. J Asthma. 2005 Dec;42(10):873-8 - PubMed
  6. Can Respir J. 2007 Nov-Dec;14(8):485-9 - PubMed
  7. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959-67 - PubMed
  8. Prog Med Chem. 2009;47:37-74 - PubMed
  9. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79 - PubMed
  10. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):546-51 - PubMed
  11. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56 - PubMed
  12. Am J Respir Crit Care Med. 2001 Sep 1;164(5):770-7 - PubMed
  13. Br J Pharmacol. 2008 Oct;155(3):288-90 - PubMed
  14. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69 - PubMed
  15. Clin Exp Allergy. 2009 Jun;39(6):788-97 - PubMed
  16. N Engl J Med. 2008 Oct 9;359(15):1543-54 - PubMed
  17. Am J Respir Crit Care Med. 1998 Feb;157(2):351-70 - PubMed
  18. Am J Respir Crit Care Med. 2005 Oct 1;172(7):848-53 - PubMed
  19. Eur Respir J. 2009 May;33(5):1165-85 - PubMed
  20. J Clin Pharmacol. 2007 May;47(5):660-6 - PubMed
  21. Drugs R D. 2004;5(3):176-81 - PubMed
  22. Pharmacol Rev. 2006 Sep;58(3):488-520 - PubMed
  23. J Pharmacol Exp Ther. 2001 Apr;297(1):280-90 - PubMed
  24. Lancet. 1994 Apr 23;343(8904):1006-8 - PubMed
  25. Drugs. 2003;63(23):2575-94 - PubMed
  26. Eur Respir J. 1995 May;8(5):831-3 - PubMed
  27. Biochem Pharmacol. 1992 May 28;43(10):2041-51 - PubMed
  28. J Clin Pharmacol. 2008 Aug;48(8):978-85 - PubMed
  29. Pulm Pharmacol Ther. 2008 Aug;21(4):616-23 - PubMed
  30. Br J Clin Pharmacol. 2006 Aug;62(2):138-52 - PubMed
  31. Int J Clin Pharmacol Ther. 2006 Nov;44(11):572-9 - PubMed
  32. Respirology. 2004 Jun;9(2):249-54 - PubMed
  33. Lancet. 2005 Aug 13-19;366(9485):563-71 - PubMed
  34. J Clin Pharmacol. 2002 Mar;42(3):297-303 - PubMed
  35. Am J Respir Crit Care Med. 2007 Jul 15;176(2):162-6 - PubMed
  36. Lancet. 2009 Aug 29;374(9691):695-703 - PubMed
  37. Am J Respir Cell Mol Biol. 2009 Dec;41(6):631-8 - PubMed
  38. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55 - PubMed
  39. MMWR Surveill Summ. 2002 Aug 2;51(6):1-16 - PubMed
  40. Br J Clin Pharmacol. 2008 Jun;65(6):803-10 - PubMed
  41. Pulm Pharmacol Ther. 2003;16(2):115-20 - PubMed
  42. Expert Opin Ther Pat. 2009 Nov;19(11):1501-19 - PubMed
  43. Am J Respir Crit Care Med. 2003 Oct 15;168(8):976-82 - PubMed
  44. Br J Clin Pharmacol. 2009 Oct;68(4):580-7 - PubMed
  45. Thorax. 2002 Oct;57(10):847-52 - PubMed
  46. Pulm Pharmacol Ther. 2010 Aug;23(4):283-91 - PubMed
  47. Pulm Pharmacol Ther. 2006;19(5):343-52 - PubMed
  48. Proc Am Thorac Soc. 2005;2(4):334-9; discussion 340-1 - PubMed
  49. J Clin Pharmacol. 2006 Oct;46(10):1146-53 - PubMed
  50. J Clin Pharmacol. 2007 Jan;47(1):26-36 - PubMed
  51. J Clin Invest. 2002 Oct;110(7):1045-52 - PubMed
  52. Clin Pharmacokinet. 2007;46(5):403-16 - PubMed
  53. N Engl J Med. 2004 Jun 24;350(26):2645-53 - PubMed
  54. Br J Clin Pharmacol. 2007 Mar;63(3):365-70 - PubMed
  55. Pulm Pharmacol Ther. 2007;20(1):46-51 - PubMed
  56. Br J Pharmacol. 2007 Oct;152(4):481-92 - PubMed
  57. BMC Pulm Med. 2008 Aug 28;8:17 - PubMed
  58. Pulm Pharmacol Ther. 1999;12(2):131-5 - PubMed
  59. J Clin Pharmacol. 2008 Nov;48(11):1339-49 - PubMed
  60. J Clin Pharmacol. 2009 Apr;49(4):389-97 - PubMed
  61. Am J Respir Crit Care Med. 1995 Jun;151(6):1907-14 - PubMed
  62. Am Rev Respir Dis. 1978 Aug;118(2):229-38 - PubMed
  63. Pulm Pharmacol Ther. 2003;16(2):97-104 - PubMed
  64. Pulm Pharmacol Ther. 2003;16(6):341-7 - PubMed
  65. Eur Respir J. 1996 Aug;9(8):1672-7 - PubMed
  66. J Allergy Clin Immunol. 2006 Sep;118(3):649-57 - PubMed
  67. Expert Opin Investig Drugs. 2008 May;17(5):811-8 - PubMed
  68. J Clin Pharmacol. 2007 Aug;47(8):1005-13 - PubMed
  69. Drug Metab Rev. 1979;9(2):221-36 - PubMed
  70. Drug Discov Today. 2005 Nov 15;10(22):1503-19 - PubMed
  71. Nat Rev Immunol. 2008 Mar;8(3):183-92 - PubMed
  72. Am J Respir Crit Care Med. 2007 Jul 15;176(2):154-61 - PubMed
  73. Thorax. 2007 Dec;62(12):1081-7 - PubMed
  74. Trends Pharmacol Sci. 2002 Dec;23(12):548 - PubMed
  75. Structure. 2004 Dec;12(12):2233-47 - PubMed
  76. Ann Intern Med. 2007 Apr 17;146(8):545-55 - PubMed
  77. Int J Clin Pharmacol Ther. 2009 Apr;47(4):236-45 - PubMed
  78. Thorax. 2004 Jul;59(7):574-80 - PubMed

Substances

MeSH terms

Publication Types